Breaking News
Get 50% Off 0
Unlock Premium Data: Up to 50% Off InvestingPro CLAIM SALE
Close

AstraZeneca PLC (AZN)

Create Alert
New!
Create Alert
Website
  • As an alert notification
  • To use this feature, make sure you are signed-in to your account
Mobile App
  • To use this feature, make sure you are signed-in to your account
  • Make sure you are signed-in with the same user profile

Condition

Frequency

Once
%

Frequency

Frequency

Delivery Method

Status

Add to/Remove from a Portfolio Add to Watchlist
Add to Watchlist
Add Position

Position added successfully to:

Please name your holdings portfolio
 
148.35 +0.40    +0.27%
24/06 - Closed. Currency in EUR ( Disclaimer )
  • Volume: 530
  • Bid/Ask: 147.55 / 149.00
  • Day's Range: 147.50 - 148.35
Type:  Equity
Market:  Germany
ISIN:  GB0009895292 
S/N:  886455
AstraZeneca 148.35 +0.40 +0.27%

AZN Income Statement

 
Featured here, the Income Statement (earnings report) for AstraZeneca PLC, showing the company's financial performance from operating and non operating activities such as revenue, expenses and income for the last 4 periods (either quarterly or annually).
AnnualQuarterly
Advanced Income Statement
Period Ending: 2024
31/03
2023
31/12
2023
30/09
2023
30/06
Total Revenue 12679 12024 11492 11416
Revenue 12679 12024 11492 11416
Other Revenue, Total - - - -
Cost of Revenue, Total 2198 2295 2055 1917
Gross Profit 10481 9729 9437 9499
Total Operating Expenses 9369 9990 8959 8814
Selling/General/Admin. Expenses, Total 4533 4891 4440 5054
Research & Development 2703 2935 2534 2627
Depreciation / Amortization 300 -790 268 259
Interest Expense (Income) - Net Operating -413 -38 -392 -431
Unusual Expense (Income) - - - -
Other Operating Expenses, Total 48 697 54 -612
Operating Income 3310 2034 2533 2602
Interest Income (Expense), Net Non-Operating - - - -
Gain (Loss) on Sale of Assets - 51 - -
Other, Net 510 1086 881 514
Net Income Before Taxes 2800 897 1652 2088
Provision for Income Taxes 620 -62 274 268
Net Income After Taxes 2180 959 1378 1820
Minority Interest 56 23 24 24
Equity In Affiliates - - - -
U.S GAAP Adjustment - - - -
Net Income Before Extraordinary Items 2179 960 1374 1818
Total Extraordinary Items - - - -
Net Income 2179 960 1374 1818
Total Adjustments to Net Income - - - -
Income Available to Common Excluding Extraordinary Items 2179 960 1374 1818
Dilution Adjustment -5 0.78 1.2 -7.2
Diluted Net Income 2184 959.22 1372.8 1825.2
Diluted Weighted Average Shares 1560 1561 1560 1560
Diluted EPS Excluding Extraordinary Items 1.4 0.614 0.88 1.17
DPS - Common Stock Primary Issue - 1.97 - 0.93
Diluted Normalized EPS 1.2 0.695 0.891 0.894
* In Millions of USD (except for per share items)
InvestingPro
Go to Dashboard InvestingPro

Unlock access to over 1000 metrics with InvestingPro

View advanced insights on the income statement, including growth rates and metrics that provide an in-depth view of the company's historical and forecasted financial performance.

 
Comment Guidelines

We encourage you to use comments to engage with users, share your perspective and ask questions of authors and each other. However, in order to maintain the high level of discourse we’ve all come to value and expect, please keep the following criteria in mind: 

  • Enrich the conversation
  • Stay focused and on track. Only post material that’s relevant to the topic being discussed.
  • Be respectful. Even negative opinions can be framed positively and diplomatically.
  •  Use standard writing style. Include punctuation and upper and lower cases.
  • NOTE: Spam and/or promotional messages and links within a comment will be removed
  • Avoid profanity, slander or personal attacks directed at an author or another user.
  • Don’t Monopolize the Conversation. We appreciate passion and conviction, but we also believe strongly in giving everyone a chance to air their thoughts. Therefore, in addition to civil interaction, we expect commenters to offer their opinions succinctly and thoughtfully, but not so repeatedly that others are annoyed or offended. If we receive complaints about individuals who take over a thread or forum, we reserve the right to ban them from the site, without recourse.
  • Only English comments will be allowed.

Perpetrators of spam or abuse will be deleted from the site and prohibited from future registration at Investing.com’s discretion.

AZN Comments

Write your thoughts about AstraZeneca
 
Are you sure you want to delete this chart?
 
Post
Post also to:
 
Replace the attached chart with a new chart ?
1000
Your ability to comment is currently suspended due to negative user reports. Your status will be reviewed by our moderators.
Please wait a minute before you try to comment again.
Thanks for your comment. Please note that all comments are pending until approved by our moderators. It may therefore take some time before it appears on our website.
Oct 28, 2021 0:25
Saved. See Saved Items.
This comment has already been saved in your Saved Items
Double top in reach
 
Are you sure you want to delete this chart?
 
Post
 
Replace the attached chart with a new chart ?
1000
Your ability to comment is currently suspended due to negative user reports. Your status will be reviewed by our moderators.
Please wait a minute before you try to comment again.
Add Chart to Comment
Confirm Block

Are you sure you want to block %USER_NAME%?

By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.

%USER_NAME% was successfully added to your Block List

Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.

Report this comment

I feel that this comment is:

Comment flagged

Thank You!

Your report has been sent to our moderators for review
Continue with Google
or
Sign up with Email